News
SLN
19.80
+0.15%
0.03
Silence Therapeutics GAAP EPS of -$0.08 beats by $0.05
Seeking Alpha · 13h ago
Silence Therapeutics GAAP EPS of -$0.08
Seeking Alpha · 13h ago
Silence Therapeutics Q3 EPS $(0.24) Misses $(0.12) Estimate
Benzinga · 13h ago
Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results
Barchart · 20h ago
J&J gets into psychedelic treatments with backing of Delix Therapeutics
Seeking Alpha · 3d ago
Weekly Report: what happened at SLN last week (1102-1106)?
Weekly Report · 3d ago
Weekly Report: what happened at SLN last week (1026-1030)?
Weekly Report · 11/02 10:25
Weekly Report: what happened at SLN last week (1019-1023)?
Weekly Report · 10/26 10:25
Key deals this week: Visa, London Stock Exchange, Tradeweb Markets, Salesforce, and more
Seeking Alpha · 10/24 19:15
Silence Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silence Therapeutics plc - SLN
Barchart · 10/21 14:35
Silence Therapeutics Price Target Cut to $20.00/Share From $75.00 by HC Wainwright & Co.
Dow Jones · 10/21 11:57
Silence Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones · 10/21 11:57
HC Wainwright & Co. Downgrades Silence Therapeutics to Neutral, Lowers Price Target to $20
Benzinga · 10/21 11:48
Silence Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
TipRanks · 10/21 11:25
Nasdaq Jumps Over 1% As Tech Stocks Gain: Investor Sentiment Improves, Greed Index Remains In ‘Extreme Fear’ Zone
Benzinga · 10/20 08:32
Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today
Benzinga · 10/20 01:04
Silence Therapeutics: Downgrade To Hold On Merck KGaA Acquisition And PV siRNA
Seeking Alpha · 10/19 21:23
Silence Therapeutics downgraded to Hold from Buy at Jefferies
TipRanks · 10/19 18:05
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 10/19 17:05
Why Is Silence Therapeutics Stock Skyrocketing Monday?
Benzinga · 10/19 17:00
More
Webull provides a variety of real-time SLN stock news. You can receive the latest news about Silence Therapeutics Plc through multiple platforms. This information may help you make smarter investment decisions.
About SLN
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.